Extensively drug-resistant (XDR) tuberculosis (TB) threatens the global control of TB worldwide. Lisbon has a high XDR-TB rate [50% of the multidrug-resistant tuberculosis (MDR-TB)], which is mainly associated with Lisboa family strains. Few studies have addressed the identification of mutations associated with resistance to second-line injectable drugs, and the relative frequency of such mutations varies geographically. The aim of this study was to characterize the genetic changes associated with the high number of XDR-TB cases in Lisbon.
Introduction
Extensive drug resistance poses a serious threat to tuberculosis (TB) management. Extensively drug-resistant TB (XDR-TB) is defined as multidrug resistance, i.e. resistance to at least isoniazid and rifampicin, plus resistance to a fluoroquinolone and any of the injectable second-line drugs (amikacin, capreomycin or kanamycin). 1 At least four different antimycobacterial drug classes are required for an adequate treatment, and in the majority of the XDR-TB cases there are not enough options. 2 Resistance to fluoroquinolones and second-line injectable drugs is indeed associated with poor outcomes. 3 As a consequence, such strains are very difficult not only to treat but also to eliminate.
In recent years Portugal has had TB rates above the European Union (EU) average, especially if we consider only the first 15 countries that joined the EU (EU-15) and in which Portugal is included. 4 Ten years ago, some of us described a family of strains causing a multidrug-resistant (MDR) TB outbreak in the Lisbon Health Region. This family was later designated as the Lisboa family. 5 More recently, in one of our latest reports, we analysed a panel of MDR isolates and observed that 50% were XDR-TB isolates; to our knowledge, the highest XDR-TB rate ever reported.
Methods

Clinical isolates
We analysed 26 XDR-TB clinical isolates, each corresponding to a different patient. These isolates were recovered from several hospital units and laboratories of Lisbon's Health Region during 2005, and correspond to 74.3% of all the XDR-TB isolated in this region, in this year. The remaining isolates were unviable and so were not processed. Our laboratory received samples from 67 new and previously treated MDR-TB cases, 35 (52.2%) being XDR-TB.
Drug susceptibility testing
Isolates were tested for first-line drug susceptibility by the BACTEC 960 MGIT methodology according to the manufacturer's instructions. MDR-TB isolates were tested for second-line drug susceptibility by radiometric BACTEC 460, as previously described. 6 
PCR amplification and DNA sequencing
A 981 bp fragment, containing the tlyA gene, was amplified by PCR using tlyAF3 (AAGGCATCGCACGTCGTCTTTCC) and tlyAR3 (TGTCGCCCAA TACTTTTTCTACGC) primers; the region between positions 1151 and 1590 of the rrs gene was amplified by PCR using primers RRS2-F (TGCCGGGGTCAACTCGGAGG) and RRS2-R (GAACCCCTCACGGCCTACGC); and a 320 bp (78-397) internal fragment of the gyrA gene was amplified by PCR with oligonucleotide primers gyrA-F (CAGCTACATCGACTATGCGA) and gyrA-R (GGGCTTCGGTGTACCTCAT). Cycling conditions were as follows: denaturation at 948C for 4 min; 35 cycles of denaturation at 948C for 1 min, annealing at 588C (558C for gyrA) for 1 min and extension at 728C for 2 min and 30 s (1 min for gyrA); and, lastly, a final extension step at 728C for 10 min. Crude DNA extracts of each isolate were used in all molecular biology reactions.
Prior to sequencing, the amplified fragments were purified using MSB w Spin PCRapace (Invitek w ). The sequencing reactions were carried out using the BigDye Terminator Cycle Sequencing Kit with AmpliTaq DNA polymerase (Applied Biosystems w ) using primers tlyAF1 (GTTGTTGGCCG CCCTGGAGT) and tlyAR1 (GGTCTCGGTGGCTTCGTCGC), RRS2-R or gyrA-F as appropriate.
All the mutations found were compared with those included in the TB Drug Resistance Mutation Database (www.tbdreamdb.com).
MIRU-VNTR ('mycobacterial interspersed repetitive unit-variable number of tandem repeats') genotyping
All isolates were also genotyped by the 12 loci MIRU-VNTR as described previously. 6 
Statistical analysis
The statistical association between clusters and/or mutations was done using a two-tailed Fisher's exact test in GraphPad Prism w Version 4.00 (GraphPad Software, Inc.).
Results
For this study we analysed 26 different XDR-TB isolates collected from Lisbon Health Region's hospital units during 2005. In order to determine the possible molecular basis for resistance to fluoroquinolones and injectable second-line drugs the isolates were screened for mutations in three genes-gyrA, rrs and tlyA. We preferentially screened the gyrA gene and not gyrB in this set of isolates since previous results on Lisbon fluoroquinolone-resistant isolates indicate that gyrB mutations associated with resistance are absent in these strains (R. Macedo, unpublished results). We identified three different missense mutations in GyrA (D94A, D94G and S91P), the most common being mutation S91P, which was present in 11 (42.3%) isolates (Table 1) .
Concerning the mutations associated with resistance to second-line drugs, all the analysed isolates, except one, had mutations occurring in either tlyA or rrs. Occurrence of a mutation in the tlyA gene was associated with the nonoccurrence of a mutation in the rrs gene (Fisher's exact test, P ¼ 0.0010). The most prevalent mutations found in those genes were A1401G in rrs and a newly described frameshift mutation in tlyA, Ins755GT, which was present in 42.3% of the analysed isolates (Table 1) .
When comparing genotypes, isolates were divided into two large MIRU-VNTR clusters ( Table 2) . One of the clusters belongs to the highly predominant Lisboa family and the other was previously designated as Q1 and has a high genetic similarity to Lisboa strains. We verified that mutations occurring in gyrA, rrs and tlyA genes were cluster associated. GyrA D94A and rrs A1401G occurred exclusively in cluster Q1, and GyrA D94G, GyrA S91P and tlyA Ins755GT were exclusive to the Lisboa3 cluster (Table 2 ). Different mutations in the same codon (GyrA94) were concordant with the MIRU-VNTR clustering analysis. Eleven of 17 fluoroquinolone-resistant isolates in the Lisboa3 cluster had the GyrA S91P mutation, which was strongly associated with the tlyA Ins755GT mutation (Fisher's exact test, P,0.0001). In cluster Q1, eight isolates had the GyrA D94A mutation, which was associated with the rrs A1401G mutation (Fisher's exact test, P,0.0001). Such isolates, in both clusters, None of the mutations associated with resistance found in this study was detected in susceptible strains.
Discussion
We have examined the main genes associated with resistance to fluoroquinolones and injectable second-line drugs-gyrA, rrs and tlyA. The mutations found in the gyrA gene have been previously described as associated with fluoroquinolone resistance, and our results support this.
In contrast, the screening of rrs and tlyA yielded mutations not previously described. Twenty-five isolates displayed mutations in at least one of these genes and only three isolates had simultaneous mutations in both genes. Our results also indicate that only a subset of the mutations conferring kanamycin resistance actually confers resistance to amikacin. 7, 8 The data seem to support the perception that resistance to amikacin is associated with A1401G mutations but not with tlyA mutations, while 11 kanamycin-resistant isolates exhibited tlyA mutations only. However, in a study by Maus et al. 9 nonsense tlyA mutants remained susceptible to kanamycin and amikacin, which indicates that tlyA mutations probably have no role in resistance to these second-line aminoglycosides. We cannot, however, exclude the existence of mutations outside the analysed loci, since mutants resistant to kanamycin with no tlyA or rrs mutations have been found. In addition, our results support previous findings in that mutations in rrs can mediate cross-resistance between capreomycin, kanamycin and amikacin. 7 On the other hand, our results clearly differ from the results obtained by Jugheli et al., 8 who have found no mutations in the tlyA gene of 145 isolates of which 78 and 66 were kanamycin and capreomycin resistant, respectively. Perdigão et al.
A new reverse hybridization-based test to screen for cultured XDR-TB isolates, GenoType MTBDRsl (Hain Lifescience, GmbH, Nehren, Germany), 10 is already available commercially. This new test detects mutations associated with resistance to second-line injectable drugs and fluoroquinolones. According to results obtained in our study, this test would have been able to detect 96.2% of the fluoroquinolone resistance and 34.6% of the resistance to capreomycin, kanamycin or amikacin. Since resistance-associated mutations vary geographically, we therefore stress the need for knowledge concerning the prevalence of such mutations before in situ implementation of these commercial assays.
Another important conclusion concerns the clonality of the analysed strains. These strains were shown to be highly clonal, belonging to one of two close genetic clusters. Also important was the evidence that a large proportion of the analysed cases (73.1%) were possibly primary XDR-TB. This shows that the appropriate means to avoid transmission are not in place since active transmission of these deadly forms of TB is taking place.
The strains analysed in this study are highly resistant, presenting clinicians with few options. Four to six drugs would be necessary to treat these patients and only 4 of the 26 isolates in this study appear to be susceptible to at least four of these drugs. In the remaining isolates, the so-called third-line drugs (clofazimine, linezolid, amoxicillin/clavulanate, imipenem and macrolides), which have in vitro activity but with limited clinical data, should be explored. 2 The present study has, consequently, important implications for the treatment, diagnosis and epidemiology of XDR-TB in the Portuguese setting. Also, it contributes to the global awareness of XDR/MDR-TB and the urgency for new therapeutic options and novel molecular diagnosis tests adapted to specific settings. This study also highlights the utmost importance of strict regulation in the prescription of antibacillary drugs, without which it is impossible to effectively control and eliminate TB, even with new antibacillary drugs.
